Cargando…

CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease

OBJECTIVE: To measure CSF levels of biomarkers reflecting microglia and astrocytes activation, neuroinflammation, and cerebrovascular changes and study their associations with the core biomarkers of Alzheimer disease (AD) pathology (β-amyloid [Aβ] and tau), structural imaging correlates, and clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Janelidze, Shorena, Mattsson, Niklas, Stomrud, Erik, Lindberg, Olof, Palmqvist, Sebastian, Zetterberg, Henrik, Blennow, Kaj, Hansson, Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133624/
https://www.ncbi.nlm.nih.gov/pubmed/30054439
http://dx.doi.org/10.1212/WNL.0000000000006082
_version_ 1783354555263614976
author Janelidze, Shorena
Mattsson, Niklas
Stomrud, Erik
Lindberg, Olof
Palmqvist, Sebastian
Zetterberg, Henrik
Blennow, Kaj
Hansson, Oskar
author_facet Janelidze, Shorena
Mattsson, Niklas
Stomrud, Erik
Lindberg, Olof
Palmqvist, Sebastian
Zetterberg, Henrik
Blennow, Kaj
Hansson, Oskar
author_sort Janelidze, Shorena
collection PubMed
description OBJECTIVE: To measure CSF levels of biomarkers reflecting microglia and astrocytes activation, neuroinflammation, and cerebrovascular changes and study their associations with the core biomarkers of Alzheimer disease (AD) pathology (β-amyloid [Aβ] and tau), structural imaging correlates, and clinical disease progression over time. METHODS: The study included cognitively unimpaired elderly (n = 508), patients with mild cognitive impairment (MCI, n = 256), and patients with AD dementia (n = 57) from the longitudinal Swedish BioFINDER cohort. CSF samples were analyzed for YKL-40, interleukin (IL)–6, IL-7, IL-8, IL-15, IP-10, monocyte chemoattractant protein 1, intercellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1), placental growth factor, and fms-related tyrosine kinase 1 (Flt-1). MRI data were available from 677 study participants. Longitudinal clinical assessments were conducted in control individuals and patients with MCI (mean follow-up 3 years, range 1–6 years). RESULTS: CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were increased during the preclinical, prodromal, and dementia stages of AD. High levels of these biomarkers were associated with increased CSF levels of total tau, with the associations, especially for YKL-40, being stronger in Aβ-positive individuals. The results were similar for associations between phosphorylated tau and YKL-40, ICAM-1, and VCAM-1. High levels of the biomarkers were also associated with cortical thinning (primarily in the precuneus and superior parietal regions) and with subsequent cognitive deterioration in patients without dementia as measured with Mini-Mental State Examination (YKL-40) and Clinical Dementia Rating Sum of Boxes (YKL-40, ICAM-1, VCAM-1 and IL-15). Finally, higher levels of CSF YKL-40, ICAM-1, and Flt-1 increased risk of development of AD dementia in patients without dementia. CONCLUSIONS: Neuroinflammation and cerebrovascular dysfunction are early events occurring already at presymptomatic stages of AD and contribute to disease progression.
format Online
Article
Text
id pubmed-6133624
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-61336242018-09-12 CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease Janelidze, Shorena Mattsson, Niklas Stomrud, Erik Lindberg, Olof Palmqvist, Sebastian Zetterberg, Henrik Blennow, Kaj Hansson, Oskar Neurology Article OBJECTIVE: To measure CSF levels of biomarkers reflecting microglia and astrocytes activation, neuroinflammation, and cerebrovascular changes and study their associations with the core biomarkers of Alzheimer disease (AD) pathology (β-amyloid [Aβ] and tau), structural imaging correlates, and clinical disease progression over time. METHODS: The study included cognitively unimpaired elderly (n = 508), patients with mild cognitive impairment (MCI, n = 256), and patients with AD dementia (n = 57) from the longitudinal Swedish BioFINDER cohort. CSF samples were analyzed for YKL-40, interleukin (IL)–6, IL-7, IL-8, IL-15, IP-10, monocyte chemoattractant protein 1, intercellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1), placental growth factor, and fms-related tyrosine kinase 1 (Flt-1). MRI data were available from 677 study participants. Longitudinal clinical assessments were conducted in control individuals and patients with MCI (mean follow-up 3 years, range 1–6 years). RESULTS: CSF levels of YKL-40, ICAM-1, VCAM-1, IL-15, and Flt-1 were increased during the preclinical, prodromal, and dementia stages of AD. High levels of these biomarkers were associated with increased CSF levels of total tau, with the associations, especially for YKL-40, being stronger in Aβ-positive individuals. The results were similar for associations between phosphorylated tau and YKL-40, ICAM-1, and VCAM-1. High levels of the biomarkers were also associated with cortical thinning (primarily in the precuneus and superior parietal regions) and with subsequent cognitive deterioration in patients without dementia as measured with Mini-Mental State Examination (YKL-40) and Clinical Dementia Rating Sum of Boxes (YKL-40, ICAM-1, VCAM-1 and IL-15). Finally, higher levels of CSF YKL-40, ICAM-1, and Flt-1 increased risk of development of AD dementia in patients without dementia. CONCLUSIONS: Neuroinflammation and cerebrovascular dysfunction are early events occurring already at presymptomatic stages of AD and contribute to disease progression. Lippincott Williams & Wilkins 2018-08-28 /pmc/articles/PMC6133624/ /pubmed/30054439 http://dx.doi.org/10.1212/WNL.0000000000006082 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Janelidze, Shorena
Mattsson, Niklas
Stomrud, Erik
Lindberg, Olof
Palmqvist, Sebastian
Zetterberg, Henrik
Blennow, Kaj
Hansson, Oskar
CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
title CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
title_full CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
title_fullStr CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
title_full_unstemmed CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
title_short CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease
title_sort csf biomarkers of neuroinflammation and cerebrovascular dysfunction in early alzheimer disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133624/
https://www.ncbi.nlm.nih.gov/pubmed/30054439
http://dx.doi.org/10.1212/WNL.0000000000006082
work_keys_str_mv AT janelidzeshorena csfbiomarkersofneuroinflammationandcerebrovasculardysfunctioninearlyalzheimerdisease
AT mattssonniklas csfbiomarkersofneuroinflammationandcerebrovasculardysfunctioninearlyalzheimerdisease
AT stomruderik csfbiomarkersofneuroinflammationandcerebrovasculardysfunctioninearlyalzheimerdisease
AT lindbergolof csfbiomarkersofneuroinflammationandcerebrovasculardysfunctioninearlyalzheimerdisease
AT palmqvistsebastian csfbiomarkersofneuroinflammationandcerebrovasculardysfunctioninearlyalzheimerdisease
AT zetterberghenrik csfbiomarkersofneuroinflammationandcerebrovasculardysfunctioninearlyalzheimerdisease
AT blennowkaj csfbiomarkersofneuroinflammationandcerebrovasculardysfunctioninearlyalzheimerdisease
AT hanssonoskar csfbiomarkersofneuroinflammationandcerebrovasculardysfunctioninearlyalzheimerdisease